Nature Communications (Mar 2021)

Virus-specific memory T cell responses unmasked by immune checkpoint blockade cause hepatitis

  • James A. Hutchinson,
  • Katharina Kronenberg,
  • Paloma Riquelme,
  • Jürgen J. Wenzel,
  • Gunther Glehr,
  • Hannah-Lou Schilling,
  • Florian Zeman,
  • Katja Evert,
  • Martin Schmiedel,
  • Marion Mickler,
  • Konstantin Drexler,
  • Florian Bitterer,
  • Laura Cordero,
  • Lukas Beyer,
  • Christian Bach,
  • Josef Koestler,
  • Ralph Burkhardt,
  • Hans J. Schlitt,
  • Dirk Hellwig,
  • Jens M. Werner,
  • Rainer Spang,
  • Barbara Schmidt,
  • Edward K. Geissler,
  • Sebastian Haferkamp

DOI
https://doi.org/10.1038/s41467-021-21572-y
Journal volume & issue
Vol. 12, no. 1
pp. 1 – 15

Abstract

Read online

Checkpoint blocking therapies are used to treat metastatic melanoma, but can have adverse immune-mediated effects, including liver pathology. Here the authors identify an expanded pool of CD4+ effector memory T cells resulting from prior CMV exposure as a risk factor for this adverse effect in these patients.